Recent

% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

  • Networthdev Networthdev Feb 19, 2007 9:37 AM Flag

    Study finds drug Avastin helps brain tumors

    WASHINGTON, Feb 19 (Reuters) - Avastin, one of a new family of drugs that starves tumors of their blood supply, can slow the growth of the most common and deadly form of brain cancer, researchers reported on Monday.

    Avastin combined with standard chemotherapy could temporarily stop the growth of brain tumors known as gliomas, the researchers reported in the journal Clinical Cancer Research.

    Made by Genentech (DNA.N: Quote, Profile , Research) under the chemical name bevacizumab, Avastin is currently approved to treat lung and colorectal cancers.

    "These results are exciting because of the possible implications for a patient population that currently has the poorest possible prognosis going into treatment -- those with malignant brain tumors that have recurred after initial treatment," said Dr. James Vredenburgh of Duke University, who led the study.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So how is this to be interpreted?

      On the positive side, I suppose, it further validates this type of therapy which is also the vegf trap approach.

      But, on the other hand, we have Avastin approved for three indications with vegf trap a number of years away from approval for one.

      Does this news in fact point to difficulty for the profitability of vegf trap?

      Not saying I know this, just asking the question.

      • 1 Reply to martian_65
      • I take it very positively. Validates where we are heading. Look at all the satins (Lipitor, Vitoren, Crestor etc... etc...) in the market and how they all make money and big money at that. We have a solution to not just one problem/disease but several. Everyone's body is a little different, so different drugs and or combinations of drugs will be more successful/effective in one case versus another.

 
REGN
513.88-2.12(-0.41%)May 22 3:59 PMEDT